Condition: Malignant Peripheral Nerve Sheath Tumor (MPNST) · Neurofibromatosis 1 (NF1) · Atypical Neurofibroma · Sponsor: AeRang Kim
This is a phase 0/1/2, multi-site study to evaluate the MEK inhibitor Selumetinib with the MDM2 Inhibitor APG-115 in patients with Neurofibromatosis Type 1 and pre-malignant and malignant peripheral nerve sheath tumors
This description comes directly from the study's public registry record.
Vidya Chenji · 202-476-3745 · nchenji@childrensnational.org
Always discuss trial participation with your own doctor first.
| Children's National Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| UT Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06735820